Back to top
more

BioMarin Pharmaceutical (BMRN)

(Real Time Quote from BATS)

$59.45 USD

59.45
885,224

-1.22 (-2.01%)

Updated Aug 7, 2025 01:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

by Zacks Equity Research

BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.

    Tirthankar Chakraborty headshot

    New Strong Buy Stocks for May 5th

    by Tirthankar Chakraborty

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

      Zacks Equity Research

      Why Earnings Season Could Be Great for BioMarin (BMRN)

      by Zacks Equity Research

      BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

        Arpita Dutt headshot

        Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update

        by Arpita Dutt

        Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.

          Zacks Equity Research

          What Lies Ahead for Stericycle (SRCL) this Earnings Season?

          by Zacks Equity Research

          Waste management firm Stericycle, Inc. (SRCL) is scheduled to report first-quarter 2017 results after the closing bell on May 4.

            Zacks Equity Research

            Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?

            by Zacks Equity Research

            Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.

              Zacks Equity Research

              BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?

              by Zacks Equity Research

              We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

                Arpita Dutt headshot

                Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

                by Arpita Dutt

                Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed

                  by Arpita Dutt

                  Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.

                    Arpita Dutt headshot

                    5 Drug Stocks That Could Be Big Winners this Earnings Season

                    by Arpita Dutt

                    Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.

                      Arpita Dutt headshot

                      4 FDA Decisions to Watch Out for in Apr 2017

                      by Arpita Dutt

                      Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.

                        Zacks Equity Research

                        Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?

                        by Zacks Equity Research

                        BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Zacks Equity Research

                          Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse

                          by Zacks Equity Research

                          We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.

                            Zacks Equity Research

                            Repros (RPRX) Q4 Earnings: What's in Store for the Stock?

                            by Zacks Equity Research

                            Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.

                              Zacks Equity Research

                              Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?

                              by Zacks Equity Research

                              Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.

                                Zacks Equity Research

                                Inovio (INO): What's in the Cards this Earnings Season?

                                by Zacks Equity Research

                                Inovio Pharmaceuticals, Inc. (INO) is expected to report fourth-quarter 2016 results this month. The company incurred wider-than-expected loss in the last quarter.

                                  Zacks Equity Research

                                  BioDelivery (BDSI): What's in Store this Earnings Season?

                                  by Zacks Equity Research

                                  BioDelivery Sciences International, Inc. (BDSI) is expected to report fourth-quarter 2016 results on Mar 17, before the opening bell. Last quarter, the company???s loss was wider than expected.

                                    Zacks Equity Research

                                    What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

                                    by Zacks Equity Research

                                    Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

                                      Zacks Equity Research

                                      Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

                                      by Zacks Equity Research

                                      Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.

                                        Zacks Equity Research

                                        Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?

                                        by Zacks Equity Research

                                        Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

                                          by Arpita Dutt

                                          Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.

                                            Zacks Equity Research

                                            BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat

                                            by Zacks Equity Research

                                            BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.

                                              Zacks Equity Research

                                              Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More

                                              by Zacks Equity Research

                                              The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

                                                by Arpita Dutt

                                                While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

                                                  Zacks Equity Research

                                                  BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?

                                                  by Zacks Equity Research

                                                  We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23